anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Adults:The recommended starting dose of Flunisolide Nasal Solution is 2 sprays (50 mcg) in each nostril 2 times a day (total dose 200 mcg/day). If needed, this dose may be increased to 2 sprays in each nostril 3 times a day (total dose 300 mcg/day). 

Pediatric Patients 6 to 14 years:The recommended starting dose of Flunisolide Nasal Solution is 1 spray (25 mcg) in each nostril 3 times a day or 2 sprays (50 mcg) in each nostril 2 times a day (total dose 150 to 200 mcg/day). Flunisolide Nasal Solution is not recommended for use in pediatric patients less than 6 years of age as safety and efficacy studies, including possible adverse effects on growth, have not been conducted. 

Maximum total daily doses should not exceed 8 sprays in each nostril for adults (total dose 400 mcg/day) and 4 sprays in each nostril for pediatric patients under 14 years of age (total dose 200 mcg/day). Since there is no evidence that exceeding the maximum recommended dosage is more effective and increased systemic absorption would occur, higher doses should be avoided.

After the desired clinical effect is obtained, the maintenance dose should be reduced to the smallest amount necessary to control the symptoms. Approximately 15% of patients with perennial rhinitis may be maintained on as little as 1 spray in each nostril per day.

For priming and repriming the nasal spray unit after storage:The patient should remove the dust cover. Put two fingers on “shoulders” of pump unit, and place thumb on bottom of bottle. Push bottle with thumb FIRMLY and QUICKLY 5-6 times or until fine spray appears. Now your pump is primed. The patient must prime the pump unit again if it has not been used for 5 days or more, or if it has been disassembled for cleaning. 

Directions for Use:A patient leaflet of instructions accompanies each package of Flunisolide Nasal Solution. 

WARNING:Do not spray in eyes.
The efficacy of highly active antiretroviral therapy (HAART) is limited by the emergence of drug-resistant virus strains. Development of resistance to one or more antiretroviral drugs in a HAART regimen may result in substantial rebound viremia and require a new drug regimen. The use of virus genotyping or phenotyping to identify drugs likely to be active in an anti-retroviral experienced patient is now recommended, but these tests have limitations and their clinical utility has not yet been established. The goal of this project is to investigate the correlation between phenotype/genotype to selected antiretroviral agents and short-term change in viral load upon discontinuation of a single antiretroviral agent from a failing regimen. For the nucleoside reverse transcriptase inhibitors (NRTIs) and the protease inhibitors, resistance is poorly understood; thus, we plan to determine whether a change in viral load occurs after discontinuing these drugs. If so, we plan to correlate those changes with phenotypic and genotypic characteristics. Study participants must have a stable viral load of at least 1000 copies/ml by bDNA assay despite HAART and must be receiving one of the anti-retroviral agents designated for study:. Baseline viral load will be established by multiple bDNA sampling over a 10-day period. Next, the drug of interest will be withdrawn and the rest of the regimen maintained for either a two week (NRTIs except 3TC, protease inhibitor) or four week (3TC) discontinuation to assess for change in viral load. Finally, the withdrawn agent will be re-instituted, and serial sampling for change in viral load, genotype or phenotype will follow.
Objective: To develop and evaluate a feedback method for measuring and increasing therapists' empathic accuracy and reducing empathic errors in psychotherapy. Method: Sixteen (16) patient-therapist pairs were randomly assigned to intervention and control groups. All patients rated their own functioning using the GAF (Global Assessment of Functioning) and predicted the accuracy with which their therapists would estimate their ratings. Therapists rated the patient's GAF, predicted the patients' ratings of their own GAFs, and rated their confidence in their own predictions. In the intervention condition, therapist and patients discussed the previous session's ratings for a few minutes of the therapy session. Results: Intervention therapists showed greater empathic accuracy relative to controls on our empathy measure (t(14) = 2.69, p \< .01) and increased empathy over time on the Barrett-Lenard Empathy subscale (t(32) = 3.21, p \< .01). We also found significant effects on errors related to perceived accuracy of therapist empathy. Patients in the control group were found to perceive their therapists to be either more or less accurate than was actually the case (over/under-idealization), but such biases were not as strong in the intervention group. Similarly, therapists in the control group were likely to over-estimate their own accuracy (over-confidence) to a greater extent than intervention therapists. Affective responses to the instrument were positive overall and did not differ by condition. Conclusion: Empathy feedback and feedback concerning degrees of patient idealization and therapist confidence may be effective in improving functioning as well as in increasing empathic accuracy in psychotherapy.
The protein encoded by COQ7 is required for CoQ10 synthesis in humans, hydroxylating 3-demethoxyubiquinol (DMQ10) in the second to last steps of the pathway. COQ7 mutations lead to a primary CoQ10 deficiency syndrome associated with a pleiotropic neurological disorder. This study shows the clinical, physiological, and molecular characterization of four new cases of CoQ10 primary deficiency caused by five mutations in COQ7, three of which have not yet been described, inducing mitochondrial dysfunction in all patients. However, the specific combination of the identified variants in each patient generated precise pathophysiological and molecular alterations in fibroblasts, which would explain the differential in vitro response to supplementation therapy. Our results suggest that COQ7 dysfunction could be caused by specific structural changes that affect the interaction with COQ9 required for the DMQ10 presentation to COQ7, the substrate access to the active site, and the maintenance of the active site structure. Remarkably, patients' fibroblasts share transcriptional remodeling, supporting a modification of energy metabolism towards glycolysis, which could be an adaptive mechanism against CoQ10 deficiency. However, transcriptional analysis of mitochondria-associated pathways showed distinct and dramatic differences between patient fibroblasts, which correlated with the extent of pathophysiological and neurological alterations observed in the probands. Overall, this study suggests that the combination of precise genetic diagnostics and the availability of new structural models of human proteins could help explain the origin of phenotypic pleiotropy observed in some genetic diseases and the different responses to available therapies.
PURPOSE: A pharmaceutical composition containing Acer tegmentosum Maxim. extract or fraction is provided to ensure activity of suppressing angiogenesis and treat diabetic retinosis and various tumors. CONSTITUTION: A pharmaceutical composition having activity of suppressing angiogenesis contains 0.1~99 weight% of Acer tegmentosum Maxim. extract or fraction as an active ingredient. The extract or fraction is obtained using leave or twigs of Acer tegmentosum Maxim. The extract of Acer tegmentosum Maxim. is produced by adding water to Acer tegmentosum Maxim. and extracting at 95-105°C for 3 to 4 hours and freeze-drying or extracting with n-hexane, chloroform, or n-butanol. The fraction is obtained by extracting the extract with n-hexane, chloroform, and n-butanol in order and freeze-drying.
Hepatocellular carcinoma (HCC) is a prevalent form of primary liver cancer with a 5-year survival rate of just 18%. Ferulic acid, a natural compound found in fruits and vegetables such as sweet corn, rice bran, and dong quai, is an encouraging drug known for its diverse positive effects on the body, including anti-inflammatory, anti-apoptotic, and neuroprotective properties. Our study aimed to investigate the potential antitumor effects of ferulic acid to inhibit tumor growth and inflammation of HCC in rats. HCC was induced in rats by administering thioacetamide. Additionally, some rats were given 50 mg/kg of ferulic acid three times a week for 16 weeks. Liver function was assessed by measuring serum alpha-fetoprotein (AFP) and examining hepatic tissue sections stained with hematoxylin/eosin or anti-hypoxia induced factor-1α (HIF-1α). The hepatic mRNA and protein levels of HIF-1α, nuclear factor κB (NFκB), tumor necrosis factor-α (TNF-α), mammalian target of rapamycin (mTOR), signal transducer and activator of transcription 3 (STAT3), cMyc, and cyclin D1 were examined. The results showed that ferulic acid increased the rats' survival rate by reducing serum AFP levels and suppressing hepatic nodules. Furthermore, ferulic acid ameliorated the appearance of vacuolated cytoplasm induced by HCC, reduced apoptotic nuclei, and necrotic nodules. Finally, ferulic acid decreased the expression of HIF-1α, NFκB, TNF-α, mTOR, STAT3, cMyc, and cyclin D1. In conclusion, ferulic acid is believed to possess antitumor properties by inhibiting HCC-induced hypoxia through the suppression of HIF-1α expression. Additionally, it helps in reducing the expression of mTOR, STAT3, cMyc, and cyclin D1, thereby slowing down tumor growth. Lastly, ferulic acid reduced hepatic tissue inflammation by downregulating NFκB and TNF-α.
The present invention relates to a composition comprising a seed extract of Chionanthus retusus Lindl. & Paxton as an active ingredient for preventing or treating an aging-related degenerative disease. The seed extract of Chionanthus retusus Lindl. & Paxton in accordance with the present invention has undergone antioxidation effect measurement experiments (experiment example 1) such as an electron donating ability (EDA) measurement experiment, a superoxide dismutase (SOD)-like activity measurement experiment, a nitrite scavenging ability measurement experiment, a xanthine oxidase inhibition ability measurement experiment, etc., and influence measurement experiments (experiment example 2) such as a collagenase inhibition ability measurement experiment and an elastase inhibition ability measurement experiment to verify an excellent suppression effect for an aging-related degenerative disease, specifically, skin aging such as wrinkles. Therefore, the seed extract of Chionanthus retusus Lindl. & Paxton is useful for a pharmaceutical composition for preventing or treating an aging-involved degenerative disease, health functional food, or health supplement food.
Enasidenib (investigational product) will be started on day 1 for 28 days every 28 days for a maximum of 12 cycles. The starting dose of Enasidenib will be 100 mg once daily in every patient and may be reduced individually according to a dose modification scheme.
Pharmacological pain therapy in cancer patients is based on guideline recommendations, which, however, do not fully coincide in all aspects due to varying weighting of evidence. The present article discusses current issues including the decreasing significance of the World Health Organization (WHO) analgesic ladder, with its distinction between step 2 and 3 being increasingly questioned. Risks of nonopioid analgesics such as paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs), particularly in older populations, are discussed. Paracetamol may potentially reduce the effectiveness of immunotherapies. Aspects of administering analgesics via a feeding tube are considered. Recommendations for the treatment of episodic pain, transitioning between different opioids, and some relevant interactions are also discussed.
The invention discloses a medicine carrier and the application thereof. An active ingredient of the provided medicine carrier is a Nano particle with positive charge. The Nano particle is formed by a triblock copolymer of MPEG (methoxy polyethylene glycol)-polycaprolactone-polyphosphonate. The invention further provides medicine for treating cancer, and the active ingredient of the medicine is the Nano particle which is formed by the MPEG-polycaprolactone-polyphosphonate loading with anti-cancer medicine. As a cation type amphiphilic segmented copolymer with biocompatibility, the triblock copolymer of MPEG-polycaprolactone-polyphosphonate forms the Nano particle with positive charge and a hydrophobic core in water solution in a self-assembly manner; the stability is good, the preparation method is simple, and the repeatability is high; the hydrophobic anti-cancer medicine can be loaded into the hydrophobic core and can be combined with siRNA with negative charge, so as to form a medicine feeding system which can convey the anti-cancer medicine and the siRNA at the same time. The medicine carrier and the medicine in the invention not only have great social and economic benefits, but also have good application prospect.
A novel program to train birthing parents in contingent responding with the goal of improving neurodevelopmental outcomes in infants prenatally exposed to cannabinoids. 1 personalized coaching session per month for 12 months.
The purpose of this study is to evaluate the effectiveness of allogeneic blood stem cell transplantation in individuals with life-threatening SLE. A non-bone marrow ablative regimen consisting of total lymphoid irradiation (TLI) and anti-thymocyte globulin (ATG) will be used to condition the recipients for transplantation. Appropriately HLA-matched donors will undergo "mobilization" of their peripheral blood mononuclear cells using G-CSF and collection by apheresis.

The preparative regimen will consist of targeted low dose radiation of lymphoid tissue administered over a 2-week period of time. During the first week of irradiation, the patients will also receive the ATG treatment. Patients will be admitted to the in-patient service for the first 5 days of the transplant preparative regimen while receiving the ATG infusion. Patients will be discharged for the second half of the preparative regimen and followed in the out-patient clinic thereafter. Patients will start immunosuppressive treatment with cyclosporine and mycophenolate mofetil prior to the infusion of mobilized peripheral blood stem cells. The mycophenolate mofetil will be stopped at approximately 1 month post-transplantation and the cyclosporine will be tapered beginning at 2 months post-transplantation and discontinued by 6 months in the presence of stable blood chimerism and the absence of graft-versus-host disease. In the pre-transplant and post-transplant setting, patients will be evaluated by an integrated team of Rheumatology and BMT physicians. During the first 21-28 days post-transplantation, these evaluations will be performed on a daily or every other day basis. Patients will be clinically assessed and evaluated for engraftment of donor cells and disease response. Patients will then be followed as needed with maximum time between evaluations of 1 to 2 weeks in the first 100 days, and then monthly for 6 months and every 6 months to 12 months thereafter.
Postoperative pain is a common concern following root canal treatments (RCT), impacting both patients and oral health practitioners. This systematic review and meta-analysis aimed to evaluate the effectiveness of laser treatment modalities in reducing postoperative pain compared to conventional methods after primary and secondary RCT in permanent mature teeth. A search of three electronic databases (PubMed, ScienceDirect, and The Cochrane Library) was conducted, using a broad range of keywords and terms. Gray literature and manual searches were conducted to complement the search. The inclusion criteria included randomized clinical trials based on the objective of the secondary study. A minimum sample size of 10 participants per group and a clearly defined criterion for postoperative pain assessment were required. The characteristics of the included studies were presented as tables. The Cochrane collaboration tool RoB 2.0 was used to assess the risk of bias within each study. Two reviewers extracted the data and assessed the studies independently, and discrepancies were resolved through consultation with a third reviewer. A random-effects model was employed for meta-analysis to estimate the overall effect measure. Heterogeneity was evaluated using Cochran's Q test and the I2 index. Publication bias was explored via Funnel plots and Egger's test. Subgroup analyses and meta-regression were conducted to assess variations among laser methods and examine the influence of independent factors. The significance threshold for all analyses was set at 5% (α = 0.05). Intraoral laser therapy demonstrated no significant advantage over conventional treatments but consistently outperformed placebo, particularly from 4 to 72 h post-treatment. Low-level laser therapy provided slight pain reduction in the first 8 h, though its effectiveness diminished in retreatment scenarios. Photodynamic therapy and laser disinfection showed marginal benefits, especially shortly after treatment, with reduced efficacy in longer-term or retreatment contexts. Further research is needed to explore different applications of laser modalities and assess distinct prognostic factors in more detail.
<P>PROBLEM TO BE SOLVED: To provide a new ultrasonic contrast medium and to provide a contrasting agent and a method comprising the medium.  <P>SOLUTION: The ultrasonic contrast medium for injection provides a contrasting agent for ultrasonic echography in the form of a suspension in an aqueous carrier liquid containing a surfactant, an additive and a stabilizer and comprises a biocompatible substance which is gaseous at body temperatures. The medium is a mixture of gases (A) and (B). At least one kind of the gas (B) is present in an amount of 0.5-41 vol.% and has a molecular weight of larger than 80 daltons and the solubility thereof in water is less than 0.0283 mL gas based on 1 mL of water measured under standard conditions. The balance of the mixture is the gas (A).  <P>COPYRIGHT: (C)2007,JPO&INPIT
PROBLEM TO BE SOLVED: To obtain a 2-phenoxyaniline derivative having Na+/Ca2+ exchange system inhibitory effect, and useful for the therapy, prophylactic or the like of ischemic heart diseases, brain diseases, and renal diseases. SOLUTION: This medicinal composition is obtained by including a 2- phenoxyaniline derivative of formula I (R1 is H or a lower alkoxy; R2 and R3 are each a halogen)  e.g. 2-[4-(3,4-difluorobenzyloxy)phenoxy]aniline hydrochloride} as an active ingredient. The above-mentioned derivative is obtained by, for example, the following steps: reacting a compound of formula II with 4-hydroxyacetophenone in the presence of a base; reacting the thus produced compound with a peracid followed by deacetylation in the presence of a base, reacting the thus obtained compound with a compound of formula III in the presence of a base, and thereafter reducing the resultant compound of formula IV. The above-mentioned derivative is prepared in the form of tablets, capsules or the like, to make the derivative applicable to oral use or parenteral use. The daily dose thereof is 0.1-1,000 mg.
This invention provides compounds of the optical brightener family which may be applied to cosmetic compounds, or the preparation of local use compounds of dermatology. The compounds can make the color more uniform, more homogeneous, more intensive, more whiteness like ceramic. This compound also has the character of preventing blacking the eye socket. The present inventions relates to compositions which contain of compounds of the optical brightener family and other cosmetic compounds, such as skin bleaching agents, screening agents, anti-wrinkle agents and moisturizers. These compositions have obvious characters in the two aspects above. Besides, this invention also relates to a method of immediate whitening, the method is a treatment of the skin by applying the composition which comprising at least one compounds of the optical brightener family.
In A-PRF assigned group, one PRF will be cut into small pieces and added to the Demineralized freeze-dried bone allograft (DFDBA) in a ratio of 1:1 and the mixture is applied into the intraosseous defect, and the other will be used to prepare the membrane to cover the defect as a barrier. The mucoperiosteal flaps will be repositioned and secured in place using4-0 silk sutures.
N-Ethyl-2-pyrrolidinone-substituted flavan-3-ols (EPSFs) are a newly discovered compound class in tea with various bioactivities. This study aimed to develop a novel processing technique to enhance EPSF contents in white tea efficiently. Using optimal processing parameters of 125 °C and 30 min in a high-temperature sterilizing oven, total EPSF content significantly increased by 1.42-18.80-fold to 1.57-6.22 mg/g without impacting sensory characteristics. Metabolomics analysis revealed elevated levels of nucleosides, nucleotides, bases, theaflavins, flavonol aglycones, EPSFs, and most flavone-C-glycosides, as well as decreased levels of amino acids, procyanidins, theasinensins, several flavanols, and flavonol-O-glycosides after EPSF-enrichment treatment. Furthermore, the EPSF-enriched white tea exhibited notable anti-inflammatory effects, mitigating xylene-induced ear edema in mice and carrageenan-induced paw edema and cotton ball-induced granulomas in rats. This study developed a new processing technique for highly efficient enhancement of EPSFs in white tea and demonstrated that EPSF-enriched white tea has a potential to serve as effective anti-inflammatory dietary supplement.
Chronic kidney disease is detected in 8-15% of the world's population. Along with fibrotic changes, it can lead to a complete loss of organ function. Therefore, a better understanding of the onset of the pathological process is required. To address this issue, we examined the interaction between mast cells (MCs) and cells in fibrous and intact regions, focusing on the role of MC proteases such as tryptase, chymase, and carboxypeptidase A3 (CPA3). MCs appear to be involved in the development of inflammatory and fibrotic changes through the targeted secretion of tryptase, chymase, and CPA3 to the vascular endothelium, nephron epithelium, interstitial cells, and components of intercellular substances. Protease-based phenotyping of renal MCs showed that tryptase-positive MCs were the most common phenotype at all anatomic sites. The infiltration of MC in different anatomic sites of the kidney with an associated release of protease content was accompanied by a loss of contact between the epithelium and the basement membrane, indicating the active participation of MCs in the formation and development of fibrogenic niches in the kidney. These findings may contribute to the development of novel strategies for the treatment of tubulointerstitial fibrosis.